Psychological side effects of immune therapies: symptoms and pathomechanism

Current Opinion in Pharmacology

Volumn 29, Issue , 2016, Pages 97-103

  Kovacs, David ^a   Kovacs, Peter ^a,b   Eszlari, Nora ^a,c   Gonda, Xenia ^a,c   Juhasz, Gabriella ^a,c,d  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; CYTOKINE; IMMUNE CHECKPOINT INHIBITOR; IMMUNOMODULATING AGENT; NEUROTRANSMITTER; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; ANXIETY DISORDER; AUTONOMIC NEUROPATHY; CHRONIC INFLAMMATION; COGNITIVE DEFECT; DELIRIUM; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; FATIGUE; GENETIC RISK; HAIRY CELL LEUKEMIA; HEPATITIS C; HUMAN; IMMUNOTHERAPY; INSOMNIA; MAJOR DEPRESSION; MANIA; MELANOMA; MENTAL DISEASE; MENTAL STRESS; NERVE CELL PLASTICITY; NEUROTOXICITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHOSIS; PSYCHOSOMATIC DISORDER; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOCIAL SUPPORT; SYMPTOM; ADVERSE EFFECTS; CHEMICALLY INDUCED; DEPRESSIVE DISORDER, MAJOR; INFLAMMATION; PATHOPHYSIOLOGY;

DEPRESSION; DEPRESSIVE DISORDER, MAJOR; HUMANS; IMMUNOTHERAPY; INFLAMMATION; INTERFERON-ALPHA;

EID: 84978759044     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2016.06.008     Document Type: Review

References (58)

1. 1 Capuron, L., Gumnick, J.F., Musselman, D.L., Lawson, D.H., Reemsnyder, A., Nemeroff, C.B., Miller, A.H., Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26 (2002), 643–652.
2. 2 Dantzer, R., Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol 500 (2004), 399–411.
3. 3 Raison, C.L., Miller, A.H., The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D). Mol Psychiatry 18 (2013), 15–37.
4. 4•• Miller, A.H., Raison, C.L., The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 16 (2015), 22–34 This paper demonstrates that an evolutionary advantageous process, namely behavioural changes during inflammation, is an important pathomechanism in the development of social stress-induced depression.
5. 5 Sabel, M.S., Sondak, V.K., Is there a role for adjuvant high-dose interferon-alpha-2b in the management of melanoma?. Drugs 63 (2003), 1053–1058.
6. 6 Lin, F.C., Young HA:, Interferons, Success in anti-viral immunotherapy. Cytokine Growth Factor Rev 25 (2014), 369–376.
7. 7 Alexandrescu, D.T., Ichim, T.E., Riordan, N.H., Marincola, F.M., Di Nardo, A., Kabigting, F.D., Dasanu, C.A., Immunotherapy for melanoma: current status and perspectives. J Immunother 33 (2010), 570–590.
8. 8 Pestka, S., The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 282 (2007), 20047–20051.
9. 9 Lotrich, F.E., Psychiatric clearance for patients started on interferon-alpha-based therapies. Am J Psychiatry 170 (2013), 592–597.
10. 10 Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S., Foster, G.R., Kautz, A., Forton, D., Pariante, C.M., Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol 57 (2012), 1379–1390.
11. 11 Norcini Pala, A., Steca, P., Bagrodia, R., Helpman, L., Colangeli, V., Viale, P., Wainberg, M.L., Subtypes of depressive symptoms and inflammatory biomarkers: an exploratory study on a sample of HIV-positive patients. Brain Behav Immun, 2016.
12. 12 Capuron, L., Fornwalt, F.B., Knight, B.T., Harvey, P.D., Ninan, P.T., Miller, A.H., Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals?. J Affect Disord 119 (2009), 181–185.
13. 13 Kovacs, D., Eszlari, N., Petschner, P., Pap, D., Vas, S., Kovacs, P., Gonda, X., Bagdy, G., Juhasz, G., Interleukin-6 promoter polymorphism interacts with pain and life stress influencing depression phenotypes. J Neural Transm (Vienna) 123 (2016), 541–548.
14. 14 Postow, M.A., Callahan, M.K., Wolchok, J.D., Immune checkpoint blockade in cancer therapy. J Clin Oncol 33 (2015), 1974–1982.
15. 15 Kovacs, P., Panczel, G., Borbola, K., Juhasz, G., Liszkay, G., Psychological changes in melanoma patients during ipilimumab treatment compared to low-dose interferon alpha therapy — a follow-up study of first experiences. Pathol Oncol Res 20 (2014), 939–944.
16. 16 Baraldi, S., Hepgul, N., Mondelli, V., Pariante, C.M., Symptomatic treatment of interferon-alpha-induced depression in hepatitis C: a systematic review. J Clin Psychopharmacol 32 (2012), 531–543.
17. 17 Garbe, C., Radny, P., Linse, R., Dummer, R., Gutzmer, R., Ulrich, J., Stadler, R., Weichenthal, M., Eigentler, T., Ellwanger, U., et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 19 (2008), 1195–1201.
18. 18 Raison, C.L., Capuron, L., Miller, A.H., Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27 (2006), 24–31.
19. 19•• Dipasquale, O., Cooper, E.A., Tibble, J., Voon, V., Baglio, F., Baselli, G., Cercignani, M., Harrison, N.A., Interferon-alpha acutely impairs whole-brain functional connectivity network architecture — a preliminary study. Brain Behav Immun, 2015 An elegant pharmacological brain MRI study demonstrated that the first dose of IFN-alpha in hepatitis C patients can disconnect functionally coupled brain regions within hours.
20. 20 Haroon, E., Woolwine, B.J., Chen, X., Pace, T.W., Parekh, S., Spivey, J.R., Hu, X.P., Miller, A.H., IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy. Neuropsychopharmacology 39 (2014), 1777–1785.
21. 21 Capuron, L., Pagnoni, G., Demetrashvili, M., Woolwine, B.J., Nemeroff, C.B., Berns, G.S., Miller, A.H., Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry 58 (2005), 190–196.
22. 22 Miller, A.H., Maletic, V., Raison, C.L., Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65 (2009), 732–741.
23. 23 D'Mello, C., Le, T., Swain, M.G., Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J Neurosci 29 (2009), 2089–2102.
24. 24 Torres-Platas, S.G., Cruceanu, C., Chen, G.G., Turecki, G., Mechawar, N., Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. Brain Behav Immun 42 (2014), 50–59.
25. 25 Cattaneo, A., Macchi, F., Plazzotta, G., Veronica, B., Bocchio-Chiavetto, L., Riva, M.A., Pariante, C.M., Inflammation and neuronal plasticity: a link between childhood trauma and depression pathogenesis. Front Cell Neurosci, 9, 2015, 40.
26. 26 Vecsei, L., Szalardy, L., Fulop, F., Toldi, J., Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 12 (2013), 64–82.
27. 27 Tavares, R.G., Tasca, C.I., Santos, C.E., Alves, L.B., Porciuncula, L.O., Emanuelli, T., Souza, D.O., Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int 40 (2002), 621–627.
28. 28 Raison, C.L., Demetrashvili, M., Capuron, L., Miller, A.H., Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19 (2005), 105–123.
29. 29 Leonard, B., Maes, M., Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 36 (2012), 764–785.
30. 30 Romano, E., Kusio-Kobialka, M., Foukas, P.G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P., Speiser, D.E., Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A 112 (2015), 6140–6145.
31. 31 Thomas, G., Tacke, R., Hedrick, C.C., Hanna, R.N., Nonclassical patrolling monocyte function in the vasculature. Arterioscler Thromb Vasc Biol 35 (2015), 1306–1316.
32. 32 Sunshine, J., Taube, J.M., PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 23 (2015), 32–38.
33. 33 Smith, K.J., Norris, S., O'Farrelly, C., O'Mara, S.M., Risk factors for the development of depression in patients with hepatitis C taking interferon-alpha. Neuropsychiatr Dis Treat 7 (2011), 275–292.
34. 34 Moieni, M., Irwin, M.R., Jevtic, I., Olmstead, R., Breen, E.C., Eisenberger, N.I., Sex differences in depressive and socioemotional responses to an inflammatory challenge: implications for sex differences in depression. Neuropsychopharmacology 40 (2015), 1709–1716.
35. 35 Juhasz, G., Gonda, X., Hullam, G., Eszlari, N., Kovacs, D., Lazary, J., Pap, D., Petschner, P., Elliott, R., Deakin, J.F., et al. Variability in the effect of 5-HTTLPR on depression in a large European population: the role of age, symptom profile, type and intensity of life stressors. PLoS One, 10, 2015 e0116316.
36. 36 Lotrich, F.E., Ferrell, R.E., Rabinovitz, M., Pollock, B.G., Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 65 (2009), 344–348.
37. 37 Udina, M., Moreno-Espana, J., Navines, R., Gimenez, D., Langohr, K., Gratacos, M., Capuron, L., de la Torre, R., Sola, R., Martin-Santos, R., Serotonin and interleukin-6: the role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms. Psychoneuroendocrinology 38 (2013), 1803–1813.
38. 38•• Mostafavi, S., Battle, A., Zhu, X., Potash, J.B., Weissman, M.M., Shi, J., Beckman, K., Haudenschild, C., McCormick, C., Mei, R., et al. Type I interferon signaling genes in recurrent major depression: increased expression detected by whole-blood RNA sequencing. Mol Psychiatry 19 (2014), 1267–1274 This study used whole genome expression data and pathway analysis methods to show that interferon α/β signalling pathway is upregulated in recurrent MDD patients compared to controls.
39. 39• Kovacs, D., Eszlari, N., Petschner, P., Pap, D., Vas, S., Kovacs, P., Gonda, X., Juhasz, G., Bagdy, G., Effects of IL1B single nucleotide polymorphisms on depressive and anxiety symptoms are determined by severity and type of life stress. Brain Behav Immun 56 (2016), 96–104 A further support that genetic variants in the inflammatory pathway, namely polymorphisms in the IL1B gene, increase the risk of depressive and anxiety symptoms in the face of stressful life events.
40. 40 Sarginson, J.E., Deakin, J.F., Anderson, I.M., Downey, D., Thomas, E., Elliott, R., Juhasz, G., Neuronal nitric oxide synthase (NOS1) polymorphisms interact with financial hardship to affect depression risk. Neuropsychopharmacology 39 (2014), 2857–2866.
41. 41 Deinzer, R., Granrath, N., Stuhl, H., Twork, L., Idel, H., Waschul, B., Herforth, A., Acute stress effects on local Il-1beta responses to pathogens in a human in vivo model. Brain Behav Immun 18 (2004), 458–467.
42. 42 Maes, M., Song, C., Lin, A., De Jongh, R., Van Gastel, A., Kenis, G., Bosmans, E., De Meester, I., Benoy, I., Neels, H., et al. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 10 (1998), 313–318.
43. 43 Iwata, M., Ota, K.T., Li, X.Y., Sakaue, F., Li, N., Dutheil, S., Banasr, M., Duric, V., Yamanashi, T., Kaneko, K., et al. Psychological stress activates the inflammasome via release of adenosine triphosphate and stimulation of the purinergic type 2X7 receptor. Biol Psychiatry 80 (2016), 12–22.
44. 44 Danese, A., Moffitt, T.E., Pariante, C.M., Ambler, A., Poulton, R., Caspi, A., Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry 65 (2008), 409–415.
45. 45 Capuron, L., Raison, C.L., Musselman, D.L., Lawson, D.H., Nemeroff, C.B., Miller, A.H., Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 160 (2003), 1342–1345.
46. 46 Capuron, L., Ravaud, A., Miller, A.H., Dantzer, R., Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 18 (2004), 205–213.
47. 47 Giesbrecht, G.F., Poole, J.C., Letourneau, N., Campbell, T., Kaplan, B.J., Team, A.P.S., The buffering effect of social support on hypothalamic-pituitary-adrenal axis function during pregnancy. Psychosom Med 75 (2013), 856–862.
48. 48 Eisenberger, N.I., Taylor, S.E., Gable, S.L., Hilmert, C.J., Lieberman, M.D., Neural pathways link social support to attenuated neuroendocrine stress responses. Neuroimage 35 (2007), 1601–1612.
49. 49 Moieni, M., Irwin, M.R., Jevtic, I., Breen, E.C., Cho, H.J., Arevalo, J.M., Ma, J., Cole, S.W., Eisenberger, N.I., Trait sensitivity to social disconnection enhances pro-inflammatory responses to a randomized controlled trial of endotoxin. Psychoneuroendocrinology 62 (2015), 336–342.
50. 50• Kovacs, P., Panczel, G., Balatoni, T., Liszkay, G., Gonda, X., Bagdy, G., Juhasz, G., Social support decreases depressogenic effect of low-dose interferon alpha treatment in melanoma patients. J Psychosom Res 78 (2015), 579–584 Social support as a positive environmental effect is able to moderate the depressogenic effect of activation in the pro-inflammatory cytokine pathway, possibly by acting through overlapping biological processes.
51. 51• Sarkar, S., Schaefer, M., Antidepressant pretreatment for the prevention of interferon alfa-associated depression: a systematic review and meta-analysis. Psychosomatics 55 (2014), 221–234 This review demonstrated that preventive antidepressant treatment during IFN-alpha therapy effectively prevented IFN-associated depression in all patients irrespective of pre-existing psychiatric symptoms, thus can be offered to all patients.
52. 52 Chang, J.P., Lai, H.C., Yang, H.T., Su, W.P., Peng, C.Y., Galecki, P., Walczewska, A., Pariante, C.M., Su, K.P., Polyunsaturated fatty acids levels and initial presentation of somatic symptoms induced by interferon-alpha therapy in patients with chronic hepatitis C viral infection. Nutr Neurosci, 2015.
53. 53 Pariante, C.M., Neuroscience, mental health and the immune system: overcoming the brain-mind-body trichotomy. Epidemiol Psychiatr Sci, 2015, 1–5.
54. 54 Leonard, B.E., Impact of inflammation on neurotransmitter changes in major depression: an insight into the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 48 (2014), 261–267.
55. 55• Di Rosso, M.E., Palumbo, M.L., Genaro, A.M., Immunomodulatory effects of fluoxetine: a new potential pharmacological action for a classic antidepressant drug?. Pharmacol Res 109 (2016), 101–107 This review emphasises that the antidepressant fluoxetine effectively modulates the function of peripheral immune cells and may have a role in antitumor T-cell activity.
56. 56 Uher, R., Tansey, K.E., Dew, T., Maier, W., Mors, O., Hauser, J., Dernovsek, M.Z., Henigsberg, N., Souery, D., Farmer, A., et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry 171 (2014), 1278–1286.
57. 57 Husain, M.I., Chaudhry, I.B., Rahman, R.R., Hamirani, M.M., Qurashi, I., Khoso, A.B., Deakin, J.F., Husain, N., Young, A.H., Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial. Trials, 16, 2015, 410.
58. 58 Raison, C.L., Rutherford, R.E., Woolwine, B.J., Shuo, C., Schettler, P., Drake, D.F., Haroon, E., Miller, A.H., A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70 (2013), 31–41.